Literature DB >> 17459342

Aberrant hypermethylation of the FGFR2 gene in human gastric cancer cell lines.

Soonok Park1, Ji-Hyun Kim, Jun-Hyeog Jang.   

Abstract

We have previously shown that fibroblast growth factor receptor 2 (FGFR2) plays an important role in gastric carcinogenesis. In this study, we assessed DNA methylation status in the promoter region of FGFR2 gene in gastric cancer cell lines, and indicated that this region was highly methylated, compared with FGFR2-expressing gastric cancer cell lines. Moreover, the restoration of FGFR2 expression by treating methylated cells with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine strongly suggests that the loss of FGFR2 expression may be due to the aberrant hypermethylation in the promoter region of the FGFR2 gene. Thus, our results suggest that the epigenetic silencing of FGFR2 through DNA methylation in gastric cancer may contribute to tumor progression.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17459342     DOI： 10.1016/j.bbrc.2007.04.051

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  8 in total

1.  HOXC6 is deregulated in human head and neck squamous cell carcinoma and modulates Bcl-2 expression.

Authors:  Sung-Min Moon; Soo-A Kim; Jung-Hoon Yoon; Sang-Gun Ahn
Journal:  J Biol Chem       Date:  2012-08-15       Impact factor: 5.157

2.  Common variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk.

Authors:  Zhen Zhen Zhao; Pamela M Pollock; Shane Thomas; Susan A Treloar; Dale R Nyholt; Grant W Montgomery
Journal:  Hum Reprod       Date:  2008-02-18       Impact factor: 6.918

3.  Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth.

Authors:  Thomas Amann; Frauke Bataille; Thilo Spruss; Katja Dettmer; Peter Wild; Christian Liedtke; Marcus Mühlbauer; Paul Kiefer; Peter J Oefner; Christian Trautwein; Anja-Katrin Bosserhoff; Claus Hellerbrand
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

4.  Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer.

Authors:  Colleen D McCabe; Demetri D Spyropoulos; David Martin; Carlos S Moreno
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

5.  Systematic detection of putative tumor suppressor genes through the combined use of exome and transcriptome sequencing.

Authors:  Qi Zhao; Ewen F Kirkness; Otavia L Caballero; Pedro A Galante; Raphael B Parmigiani; Lee Edsall; Samantha Kuan; Zhen Ye; Samuel Levy; Ana Tereza R Vasconcelos; Bing Ren; Sandro J de Souza; Anamaria A Camargo; Andrew J G Simpson; Robert L Strausberg
Journal:  Genome Biol       Date:  2010-11-25       Impact factor: 13.583

Review 6.  Therapeutic targeting of fibroblast growth factor receptors in gastric cancer.

Authors:  Mikito Inokuchi; Yoshitaka Fujimori; Sho Otsuki; Yuya Sato; Masatoshi Nakagawa; Kazuyuki Kojima
Journal:  Gastroenterol Res Pract       Date:  2015-04-27       Impact factor: 2.260

7.  Validation of epigenetic mechanisms regulating gene expression in canine B-cell lymphoma: An in vitro and in vivo approach.

Authors:  Silvia Da Ros; Luca Aresu; Serena Ferraresso; Eleonora Zorzan; Eugenio Gaudio; Francesco Bertoni; Mauro Dacasto; Mery Giantin
Journal:  PLoS One       Date:  2018-12-11       Impact factor: 3.240

8.  Integrated Analysis of Structural Variation and RNA Expression of FGFR2 and Its Splicing Modulator ESRP1 Highlight the ESRP1amp-FGFR2norm-FGFR2-IIIchigh Axis in Diffuse Gastric Cancer.

Authors:  Sara Pinto Teles; Patrícia Oliveira; Marta Ferreira; Joana Carvalho; Pedro Ferreira; Carla Oliveira
Journal:  Cancers (Basel)       Date:  2019-12-25       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.